clinical trial · NCT06649110
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Healthy Volunteers, Pulmonary Arterial HypertensionLTPPlacebo
brief summary
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
started
Oct 24, 2024
primary completion
Nov 29, 2028
completion
Dec 31, 2028
last updated
Mar 9, 2026
detailed description
The CLTP001A12202 study will explore the safety, tolerability, and pharmacokinetics of LTP001 in healthy volunteers (Part A) and will evaluate the safety and efficacy (Part B) followed by safety extension in participants with pulmonary arterial hypertension.
official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for the Treatment of Participants With Pulmonary Arterial Hypertension (Part B)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol